<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4D8F61D8-77FA-4AD2-92CE-6EFA8E4EFE37"><gtr:id>4D8F61D8-77FA-4AD2-92CE-6EFA8E4EFE37</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Thornton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7F904BE4-7484-47DA-A7D0-426CB3039326"><gtr:id>7F904BE4-7484-47DA-A7D0-426CB3039326</gtr:id><gtr:firstName>Thomas</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Waigh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000450"><gtr:id>58A93E9F-2164-4A28-8132-8A93BFC68153</gtr:id><gtr:title>Defining the functional roles of MUC5AC and MUC5B in mucus in respiratory airways</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000450</gtr:grantReference><gtr:abstractText>Mucus is the jelly-like substance produced by the lungs to defend the body against pollution, bacteria, viruses and other environmental agents. Mucus acts to trap environmental agents and their removal from the lung is made possible by what is known as the ?mucociliary escalator?: Cells lining the surface of the large airways have tiny hairs called cilia which interact with mucus to trap and remove debris from the lungs. The beating action of the cilia moves the mucus up to the throat, where it is swallowed. 

Individuals suffering from airway diseases such as asthma, cystic fibrosis and chronic bronchitis face the constant struggle of not only making too much mucus, but that the mucus produced is stickier than normal. Such sticky mucus cannot be moved by the cilia, resulting in the airways becoming blocked.

Mucus is a complex viscous mixture made up of electrolytes, water and extremely large, rope-like molecules called mucins. There are two types of mucins in the mucus of the large airways, MUC5AC and MUC5B. In disease we know that there is a much larger amount of both mucins produced, which contributes to blocking the airways. In addition, recent research suggests that the ratio of MUC5AC and MUC5B in the mucus gel can alter how the mucus is moved by cilia, but exactly how this happens is not currently understood.

In light of this, our principal research question is: Do the two mucins, MUC5AC and MUC5B, make mucus gels which can be moved by cilia with equal efficiency, and do other components of the mucus gel interact with the mucins to alter how mucus is moved?

To answer this question, we are bringing together research teams in Biology and Physics in order to understand the distinct contributions of MUC5AC and MUC5B to the stickiness of the mucus gel. We will also find out what other molecules are critical for creating a moveable mucus gel which can be cleared from the airways. Understanding the organisation of mucus gels in health and disease will enable the design of new treatments for people suffering with airway obstruction.</gtr:abstractText><gtr:technicalSummary>Mucus accumulation in the airways is a common pathological feature of hypersecretory disease. The physical properties of the airway mucus gel are predominantly determined by two mucins, MUC5AC and MUC5B. Analysis of mucus obstructing the airways in both asthma and chronic obstructive pulmonary disease (COPD) has shown MUC5B to be the predominant mucin. However, the contribution of either mucin species to the properties of the mucus gel in not understood. In this proposal, we will investigate the hypothesis that the specific mucins MUC5AC and MUC5B and their interacting components form mucus gels with different physical properties which affects mucus transport, and hence airway clearance, by cilia action. 
To address this important question, we will employ primary airway cells in culture to produce mucus gels with different proportions of MUC5AC and MUC5B. Using a unique combination of biochemical and state of the art biophysical approaches, we will investigate three interlinked questions that are crucial to understanding the role of MUC5AC and MUC5B in this process: (1) Is it the total concentration of mucin, or the proportion of MUC5AC and MUC5B, that is of most importance in determining the physical and hence transport properties of mucus? (2) How do components that interact with mucins affect MUC5AC and/or MUC5B gel properties? (3) Does incomplete mucin maturation contribute to abnormal mucus properties? 
This study will thus establish the molecular basis of the structure and organisation of respiratory mucus gels and will help identify changes in mucus gels that contribute to hypersecretory respiratory diseases. The results will provide a basis for identifying the key components that determine the physical properties and stability of mucus gels and identify the molecular mechanisms responsible for the pathological changes in mucus that accompany chronic lung diseases. The new insight from these studies will reveal novel strategies for combating the complications caused by the production of mucus gels incapable of transport and clearance.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>368886</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>A Breath of Fresh Air - in collaboration with the Manchester museum</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C44E01C0-DEF3-4286-A8F5-7599983A1068</gtr:id><gtr:impact>A-level study day in partnership with The Manchester Museum. 19 A-level students from Manchester City College explored the issues surrounding Cystic Fibrosis research and getting to grips with considerations into funding research into cystic fibrosis, asthma and chronic obstructive pulmonary disease.

Requests to run extra sessions - two more planned this year</gtr:impact><gtr:outcomeId>R32jXjh7Pu3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.wellcome-matrix.org/foreveryone/for-schools/a-level-study-days.html</gtr:url><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D7CA83CC-35BF-4846-BDF0-071F0550F714</gtr:id><gtr:title>Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4a9c9945b67285030721168c47baaf7"><gtr:id>a4a9c9945b67285030721168c47baaf7</gtr:id><gtr:otherNames>Horsley A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1569-1993</gtr:issn><gtr:outcomeId>56cb5ef754abe7.70795873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5687BBA5-3E00-4C77-8F5E-333892041B0B</gtr:id><gtr:title>A secretory cell type develops alongside multiciliated cells, ionocytes and goblet cells, and provides a protective, anti-infective function in the frog embryonic mucociliary epidermis.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39516abb6a4df6bff8352c4c0082573e"><gtr:id>39516abb6a4df6bff8352c4c0082573e</gtr:id><gtr:otherNames>Dubaissi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>pm_540e172e1725e290a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D91D8C5-3B99-4A30-92DD-ADC34CE49DA0</gtr:id><gtr:title>Muc5b is required for airway defence.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e132936b78ad9f174a5a3e88a5e62ca3"><gtr:id>e132936b78ad9f174a5a3e88a5e62ca3</gtr:id><gtr:otherNames>Roy MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_540e172e172534f89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66CBE2CC-4F45-4262-92BB-9BB8D0CAE1DE</gtr:id><gtr:title>Mucin methods: genes encoding mucins and their genetic variation with a focus on gel-forming mucins.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca4a777b061e96e8df605cea7a887a63"><gtr:id>ca4a777b061e96e8df605cea7a887a63</gtr:id><gtr:otherNames>Rousseau K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14828_28_22259127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8209AFC4-ACC1-42DD-80ED-E911449039A9</gtr:id><gtr:title>Expression and secretion of Aspergillus fumigatus proteases are regulated in response to different protein substrates.</gtr:title><gtr:parentPublicationTitle>Fungal biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ab58ec3775d5519403a07fcb0a5948e"><gtr:id>2ab58ec3775d5519403a07fcb0a5948e</gtr:id><gtr:otherNames>Farnell E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14828_28_22954343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70755BE2-40B2-45C5-B5E3-90D7247C32D1</gtr:id><gtr:title>MUC5AC and a Glycosylated Variant of MUC5B Alter Mucin Composition in Children With Acute Asthma.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea438e567a9cbda9097c0feac95c3d65"><gtr:id>ea438e567a9cbda9097c0feac95c3d65</gtr:id><gtr:otherNames>Welsh KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5a34f3761593a0.51888496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DEDD192-4DEA-49CE-A895-E1946F21807C</gtr:id><gtr:title>Gel-forming and cell-associated mucins: preparation for structural and functional studies.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b87a58d4a9d6cb8c691675cee57b33c"><gtr:id>8b87a58d4a9d6cb8c691675cee57b33c</gtr:id><gtr:otherNames>Davies JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14828_28_22259128</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000450</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>